FDA Issues Safety Alert for Drug Spiriva
Posted on: Wednesday, 19 March 2008, 12:00 CDT
The U.S. Food and Drug Administration has issued a safety alert for Spiriva, a drug used to treat certain symptoms of chronic obstructive pulmonary disease.
The FDA said ongoing safety monitoring conducted by the drug's manufacturer -- the Boehringer Ingelheim Corp. -- has identified a possible increased risk of stroke in patients who take Spiriva to treat bronchospasm associated with COPD.
An analysis of safety data from 29 placebo controlled clinical studies estimates the risk of stroke are 8 patients per 1,000 patients treated for one year with Spiriva, and 6 patients per 1,000 patients treated for one year with placebo.
That, the FDA said, means the estimated excess risk of any type of stroke due to Spiriva is 2 patients for each 1,000 patients using Spiriva during a one year period.
The FDA said it is working with Boehringer Ingelheim to further evaluate the potential association between Spiriva and stroke. The agency said patients with questions about the new information should not stop taking Spiriva before talking with their physician.
Source: United Press International
Related Articles
- Electronic Medical Records Allow for Faster Patient Alerting to Potential Risks of Diabetes Drug, Avandia
- US FDA Grants Immtech's Oral Drug Candidate Pafuramidine (DB289) Orphan Drug Status for Treatment of PCP
- New Analysis: More Doctors on the Care Team Correlates With Higher Risk of Adverse Drug Events in Seniors
- FDA Says Impax Parkinson's Drug Not Approvable
- Nektar Announces That U.S. FDA Has Granted Orphan Drug Designation to the First Amphotericin B Inhalation Powder to Prevent Pulmonary Fungal Infections in Immunosuppressed Patients
- FDA Strengthens Warning on Drug Paxil
- Romania Has 35,000 Injecting Drug Addicts: Report
- FDA Approves New Diabetes Drug
- FDA Grants Encysive Orphan Drug Designation For Thelin
- FDA Backs Anti-Nausea Drug for Some
User Comments (0)
RSS Feeds